Brief: Affimed Reports New Data For AFM13 From Two Separate Clinical Trials

Affimed NV

01/02/2018 13:30

Feb 1 (Reuters) - Affimed Nv  AFMD.O : 
    * AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE 
CLINICAL 
TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS 
    * AFFIMED NV - DATA DEMONSTRATE THAT AFM13 WAS 
WELL-TOLERATED 
    * AFFIMED NV - DATA DEMONSTRATE AFM13 IN COMBINATION WITH 
KEYTRUDA (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN 
HODGKIN LYMPHOMA PATIENTS 
    * AFFIMED NV - EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 
IN 
CD30-POSITIVE LYMPHOMA 
    * AFFIMED NV - AFM13 IS CLINICALLY ACTIVE AND 
WELL-TOLERATED AS 
MONO- AND COMBINATION THERAPY 
    * AFFIMED NV -  AFM13 IN COMBINATION WITH KEYTRUDA WAS 
WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO 
MODERATE IN NATURE 
 
Source text for Eikon:  ID:nGNXOMVICa  
Further company coverage:  AFMD.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))